Yarrow Bioscience, Inc. (YARW)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 150K 300K 450K Q1 '21: 230K Q2 '21: 295K Q3 '21: 133K Q4 '21: 273K Q1 '22: 178K Q2 '22: 126K Q3 '22: 167K Q4 '22: 6K Q1 '23: 99K Q2 '23: 135K Q3 '23: 114K Q4 '23: 76K Q1 '24: 98K Q2 '24: 198K Q3 '24: 121K Q4 '24: 84K Q1 '25: 202K Q2 '25: 69K Q1 '26: 86K Q2 '26: 97K Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q2 '26

Gross Profit Quarterly

-4M 0 4M 8M 12M Q1 '19: 308K Q2 '19: 0 Q3 '19: 0 Q4 '19: 135K Q1 '20: 1.5M Q2 '20: 11.5M Q3 '20: 2.9M Q4 '20: 3.8M Q1 '21: -371K Q2 '21: -500K Q3 '21: -916K Q4 '21: -630K Q2 '19 Q4 '19 Q2 '20 Q4 '20 Q2 '21 Q4 '21

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-15M -10M -5M 0 5M 10M 15M Q1 '21: -9.8M Q2 '21: -9.5M Q3 '21: -10.8M Q4 '21: -8.8M Q1 '22: -8.7M Q2 '22: -8.3M Q3 '22: -9.3M Q4 '22: -8M Q1 '23: -5.9M Q2 '23: -10.3M Q3 '23: -6.2M Q4 '23: -6.8M Q1 '24: -7.4M Q2 '24: -10.4M Q3 '24: -13.1M Q4 '24: -12.8M Q1 '25: -9.2M Q2 '25: -7.5M Q1 '26: -3.8M Q2 '26: -3.1M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q2 '26

Net Income Quarterly

-24M -16M -8M 0 8M 16M 24M Q1 '21: -20.6M Q2 '21: -19.9M Q3 '21: -21.3M Q4 '21: -11.6M Q1 '22: 4.7M Q2 '22: -8.5M Q3 '22: -9.5M Q4 '22: -9.9M Q1 '23: -5.6M Q2 '23: -10.1M Q3 '23: -6.6M Q4 '23: -6.2M Q1 '24: -6.2M Q2 '24: -9.4M Q3 '24: -12.2M Q4 '24: -12M Q1 '25: -8.6M Q2 '25: -5.8M Q1 '26: -3.6M Q2 '26: -3M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 70M 140M 210M Q1 '19: 16.2M Q2 '19: 19.4M Q3 '19: 23.2M Q4 '19: 0 Q1 '20: 41.6M Q2 '20: 178.9M Q3 '20: 26.8M Q4 '20: 24.9M Q1 '21: 601K Q2 '21: 795K Q3 '21: 1M Q4 '21: 903K Q2 '19 Q4 '19 Q2 '20 Q4 '20 Q2 '21 Q4 '21

Operating Cash Flow Quarterly

-18M -12M -6M 0 6M 12M 18M Q1 '21: -12.6M Q2 '21: -16.3M Q3 '21: -17.5M Q4 '21: -10M Q1 '22: -9M Q2 '22: -8.2M Q3 '22: -7.1M Q4 '22: -4.8M Q1 '23: -5.5M Q2 '23: -9.6M Q3 '23: -5.2M Q4 '23: -5.1M Q1 '24: -8M Q2 '24: -8.5M Q3 '24: -8.5M Q4 '24: -9M Q1 '25: -11.5M Q2 '25: -10.8M Q1 '26: -4.1M Q2 '26: -2M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q4 '17: -10.2M Q4 '18: -33M Q1 '19: -16.8M Q2 '19: -13M Q3 '19: -22.2M Q4 '19: -22.4M Q1 '20: -52.3M Q2 '20: -35.9M Q3 '20: -23.6M Q4 '20: -25.4M Q1 '21: -12.6M Q2 '21: -16.3M Q3 '21: -17.5M Q4 '21: -10M Q4 '18 Q2 '19 Q4 '19 Q2 '20 Q4 '20 Q2 '21 Q4 '21

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '20: 34.7M Q3 '20: 41.9M Q1 '21: 48.9M Q2 '21: 51.4M Q3 '21: 52M Q1 '22: 3.1M Q2 '22: 3.2M Q3 '22: 3.2M Q1 '23: 3.3M Q2 '23: 3.3M Q3 '23: 3.3M Q1 '24: 42.6M Q2 '24: 42.6M Q3 '24: 42.6M Q1 '25: 42.7M Q2 '25: 855K Q1 '26: 42.8M Q2 '26: 858K Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-30.00 -20.00 -10.00 0.00 10.00 20.00 30.00 Q3 '20: 2.54 Q4 '20: -1.08 Q1 '21: -5.29 Q2 '21: -0.85 Q3 '21: -0.67 Q4 '21: -25.64 Q1 '22: -23.71 Q2 '22: -25.95 Q3 '22: -28.48 Q4 '22: -7.16 Q1 '23: -10.41 Q2 '23: -10.87 Q3 '23: -9.94 Q4 '23: -2.78 Q1 '24: -1.19 Q2 '24: 1.68 Q3 '24: 3.40 Q4 '24: -0.94 Q1 '25: -0.99 Q2 '25: -7.50 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.